Policy Notices

• RESCINDED - Prohibition on Expending NIH Grant Funds for Covered Telecommunications Equipment or Services
  (NOT-OD-21-030)
  National Institutes of Health
  

General Notices

• Notice of NIH Participation in Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science
  (NOT-OD-21-011)
  National Institutes of Health
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  

• Rollout of Redesigned eRA Commons Home and Landing Screens in January 2021
  (NOT-OD-21-028)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  Centers for Disease Control and Prevention
  Food and Drug Administration
  

• Notice of Intent to Reissue Funding Opportunity Announcements "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" to Permit Resubmissions
  (NOT-OD-21-034)
  NIH Basic Behavioral and Social Science Opportunity Network
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institutes (NCI) Frederick National Laboratory for Cancer Research
  (NOT-CA-21-018)
  National Cancer Institute
  

Notice of Changes to Funding Opportunities

• Notice of Expiration of PAR-19-370 NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
  (NOT-DE-20-034)
  National Institute of Dental and Craniofacial Research
  

• Notice of Clarification to NIEHS' Participation on PA-21-071, "Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)"
  (NOT-ES-21-004)
  National Institute of Environmental Health Sciences
  

• Notice of Change: Clarification of Page Limits for RFA-EY-20-001 "NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed)"
  (NOT-EY-21-003)
  National Eye Institute
  

• Notice of Removal of Cost Matching Requirements for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"
  (NOT-NS-21-016)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Clarification of SB1 Resubmission/Submission Policy
  (NOT-OD-21-027)
  National Institutes of Health
  

• Notice Extending Expiration Date and Adding Receipt Date for PAR-18-307: Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)
  (NOT-OD-21-031)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  

• Notice Extending Expiration Date and Adding Receipt Date for PAR-18-324: Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)
  (NOT-OD-21-032)
  Office of Disease Prevention
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Minority Health and Health Disparities
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Ocular Surface Innervation from Cell Types to Circuit Functions (U01 Clinical Trial Not Allowed)
  (NOT-EY-21-005)
  National Eye Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications
  (NOT-EB-20-017)
  National Institute of Biomedical Imaging and Bioengineering
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of General Medical Sciences
  

• Limited Competition for Emergency Competitive Revisions For Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity for Rapid Acceleration of Diagnostics Radical (RADx-rad)
  (NOT-OD-21-035)
  National Institutes of Health
  National Heart, Lung, and Blood Institute
  National Institute of Dental and Craniofacial Research
  

Funding Opportunities

• Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)
  (PAR-20-309)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021.
  
  

• Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
  (PAR-21-068)
  National Institute on Aging
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
  (PAR-21-069)
  National Institute on Aging
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Not Applicable
  
  

• NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)
  (PAR-21-084)
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 16, 2021
  
  

• Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)
  (RFA-CA-21-001)
  National Cancer Institute
  National Human Genome Research Institute
  Application Receipt Date(s): March 10, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
  (RFA-CA-21-007)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
  (RFA-CA-21-008)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional)
  (RFA-CA-21-009)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
  (RFA-CA-21-010)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement..
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
  (RFA-CA-21-011)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; Sept 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
  (RFA-CA-21-012)
  National Cancer Institute
  Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement
  
  

• GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed)
  (RFA-DK-20-013)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): February 18, 2021
  
  

• Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) /(Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed)
  (RFA-DK-20-014)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): February 18, 2021
  
  

• Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-NS-21-004)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): March 9, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)
  (RFA-NS-21-005)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): March 9, 2021 No late applications will be accepted for this Funding Opportunity Announcement